Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery

Phase 1positiveBAFAPositive

AI Analysis

Summary

Epicyt Pharma AB announced positive topline results from its Phase 1/2a first-in-human study of BAFA in patients following gastric bypass surgery, targeting impaired intestinal calcium uptake.

Clinical Trial Data

Phase

1/2a

Primary Endpoint

Met

Outcome Details

positive topline results from Phase 1/2a first-in-human study

Importance:6/10

Sentiment:

0.75

Phase 1/2afirst-in-humanpositive resultsgastric bypass surgerycalcium uptake

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 8, 2026 8:17 AM

Read Original